anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine. ^ SUBSTANCE: group of inventions relates to medicine, particularly to oncology and can be used for treating and preventing recurrence of malignant tumours in female reproductive system. According to the invention, the method involves introduction of 9-oxoacridine-10-acetic acid (CMA) and/or its pharmaceutically acceptable salt and/or its ester combined with aromatase inhibitor. The invention also pertains to use of CMA in making a medicinal agent and a set for use in the given methods. ^ EFFECT: provision for treatment and prevention of recurrence of malignant tumours in female reproductive system through potentiation of the effect of aromatase inhibitors and chemotherapeutic agents under the effect of CMA. ^ 19 cl, 9 tbl, 15 ex
General: The lacrimal sac should be compressed by digital pressure for two to three minutes after instillation to reduce excessive systemic absorption. Caution should be observed when considering use of this medication in the presence of Down's syndrome and in those predisposed to angle-closure glaucoma. 

Information for Patients: Do not touch dropper tip to any surface, as this may contaminate the solution. A transient burning sensation may occur upon instillation. Patients should be advised not to drive or engage in other hazardous activities while pupils are dilated. Patients may experience sensitivity to light and should protect eyes in bright illumination during dilation. Parents should be warned not to get this preparation in their child's mouth and to wash their own hands and the child's hands following administration. Feeding intolerance may follow ophthalmic use of this product in infants. It is recommended that feeding be withheld for four (4) hours after examination. 

Drug Interactions: Cyclopentolate may interfere with the ocular anti-hypertensive action of carbachol, pilocarpine, or ophthalmic cholinesterase inhibitors. 

Carcinogenesis, Mutagenesis, and Impairment of Fertility: Studies in animals or humans have not been conducted to evaluate the carcinogenic potential of cyclopentolate. 

Pregnancy: Pregnancy Category C. Animal reproduction studies have not been conducted with cyclopentolate. It is also not known whether cyclopentolate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Cyclopentolate should be administered to a pregnant woman only if clearly needed. 

Nursing Mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when cyclopentolate hydrochloride is administered to a nursing woman. 

Pediatric Use: Use of cyclopentolate has been associated with psychotic reactions and behavioral disturbances in pediatric patients. Increased susceptibility to cyclopentolate has been reported in infants, young children, and in children with spastic paralysis or brain damage. These disturbances include ataxia, incoherent speech, restlessness, hallucinations, hyperactivity, seizures, disorientation as to time and place, and failure to recognize people. Feeding intolerance may follow ophthalmic use of this product in infants. It is recommended that feeding be withheld for four (4) hours after examination. Observe infants closely for at least 30 minutes (see WARNINGS).
The present invention provides compositions and methods for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration or choroidal neovascularization. Certain of the compositions comprise a poxvirus complement control protein or a complement binding fragment or variant thereof (e.g. vaccina complement control protein VCP or smallpox inhibitor of completent enzymes SPICE) . Other compositions comprise a poxvirus complement control protein linked to a moiety that binds to a component present on or at the surface of cell or noncellular molecular entity, e.g., a component present in the eye of a subject at risk of or suffering from age related macular degeneration or a related condition or choroidal neovascularization. Certain of the methods comprise administering a poxvirus complement control protein or complement binding fragment or variant thereof to a subject. Compositions are disclosed which comprise a complement inhibitor an a soluble in situ gel -forming excipient (preferable soluble collagen) .
The aim of the study is to assess the impact of different surgical and antibiotic therapies on patients admitted for a septic or aseptic revision of the hip, knee or shoulder prosthesis. The decision whether the implant will be retained or removed or antimicrobial treatment is based on criteria of each participating center specialists.The success of different treatment algorithms will be measured in terms of infection free interval, functional outcome and quality of life. All consecutive patients who need a revision surgery to the hip, knee or shoulder will be included. Furthermore the study will investigate different diagnostic tests (microbiological and histological) for the diagnosis and the discrimination of septic and aseptic causes in prosthesis failures. Pathogens (microorganisms isolated from puncture of the joint, tissue samples sonication fluid and blood) will be collected to establish a biobank.The samples are obtained preoperatively and intraoperatively as part of routine care practice. The study is not randomized.
The present invention provides a Chinese medicine preparation treating liver cirrhosis and liver ascites, which is composed of the following components by weight: 5 to 7 shares of ephedra, 3 to 9 shares of speranskia, 4 to 9 shares of singlo, 10 to 20 shares of Chinese date, and 3 to 10 shares of suosuo grape. Compared with the prior art, the Chinese medicine preparation treating liver ascites of the present invention has the compatibility of the five Chinese herbal medicines, and the compatibility has the advantage of thorough syndrome differentiation, namely that the present invention analyzes the root of the disease on the basis of protecting five organs and also relieving exterior syndromes. The Chinese medicine preparation aims at causing patients to recover thoroughly. The popularization and application of the present invention can cause all the patients of liver diseases to obtain neogenesis, and can make hepatitis not damage the livers of people any longer. Accordingly, hepatitis is controlled; the evolution of hepatitis to liver cirrhosis and liver ascites is blocked; the specific disease regularity is damaged. The present invention makes contributions to improve the health level of human.
A therapeutic substance called subtiltriptasin, which is stated to have no antibacterial action, is prepared by cultivating Bacillus subtilis var. indolasus, or a mutant thereof, in a protein-free nutrient medium containing (a) at least one carbon source selected from dextrose, fructose, mannose, galastose, sorbose, sucrose, maltose, xylose, arabinose, starch, dextrin, glycerol, glycerol aldehyde, mannite, sorbite, inulin, inositol, citrates and mixtures thereof, (b) at least one nitrogen source selected from ammonium salts, amino acids and salts thereof, aliphatic amino alcohols containing an oxy group bonded to the carbon atom adjacent the amino group and an amino nitrogen having at the most two substituents preferably amino-propylene glycol, ethapolamine, diethanolamine, triethanolamine, ethylene diamine and mixtures thereof, and preferably (c) up to 0.1 per cent of at least one amino-acid; the medium being initially adjusted to pH 6.5 to 8 and cultivation being continued until at least one of said nutrients has been consumed and the medium contains at least 10,000 bacilli per c.c.  Buffers may be present.  The medium may be solid or liquid, submerged aerobic cullivation being preferred. Cultivation is for 3 to 10 days at 25 DEG  to 50 DEG  C.  The therapeutic preparations consist of (a) a fermentation broth, or an aqueous or physiological salt solution suspension obtained by washing off the B. subtilis from a solid culture medium, to which is added a preservative, (b) a powder obtained by freeze drying (a) in the presence of a filler, e.g. a carbohydrate such as lactose, (c) the filtrate from the fermentation broth, as such or after diolipis to remove impurities.  The bacilli may be alive or dead.  The preparations may be used orally, parenterally or rectally.
Patients presenting over age 11 may receive multiple drilling and be non weight bearing for up to 6 months according to the treating physician's preference. Patients with application of fixator (arthrodiastasis) will be studied in this cohort arm as well, which typically involved 3-4 months followed by 8-12 weeks of non-weight bearing after fixator removal. Other surgical techniques may be included, however these are the most common for this age group.
<P>PROBLEM TO BE SOLVED: To provide alternative and improved approaches for expression of heteroprotein.  <P>SOLUTION: These approaches typically affect expression levels, purification easiness, intracellular localization of the expression and/or immunological properties of the expression proteins. Two merits are provided. First, proteins unstable themselves or almost unexpressed can be supported by adding a suitable hybrid partner for overcoming the problems. Second, commercial production is simplified (to produce two separate useful proteins, only one expression and purification is required to be used). Accordingly, a method for simultaneous expression of two or more heteroproteins is provided and two or more of the proteins are fused (that is, these are translated as a single polypeptide chain).  <P>COPYRIGHT: (C)2011,JPO&INPIT
Hereditary TTP (hTTP), termed Upshaw-Schulman syndrome, is an ultra-rare disorder caused by a severe deficiency of plasma ADAMTS13 activity that allows circulation of ultra-large von Willebrand factor (UL-VWF) multimers. The greatest risk for hTTP is in their first days after birth, when 35-50% of patients will have severe hemolysis, jaundice, and thrombocytopenia. It is often fatal without effective treatment. In utero, fetal blood flowing from the pulmonary artery through the ductus arteriosus (DA) to the aorta is under low-shear-force. At birth, blood flow through the DA reverses to a left-to-right shunt, and the diameter of the DA begins to decrease due to hyper-oxygenated blood and decreased plasma prostaglandin E2. This causes turbulent circulation that unfolds UL-VWF, allowing platelet aggregation. If the DA closes promptly, hTTP newborns survive, but if it remains patent, turbulent circulation persists, triggering microvascular thrombosis. hTTP is commonly diagnosed as hemolytic disease of the fetus and newborn (HDFN) caused by anti-red cell antibodies and treated with exchange blood transfusion, which prevents kernicterus even when the diagnosis of hTTP is missed. The diagnosis of newborn-onset hTTP should be considered because HDFN does not cause severe thrombocytopenia, which might be effectively treated with recombinant ADAMTS13.
The invention relates to a method for preparing traditional Chinese medicine eye drops for treating cataract. The eye drops are prepared by extracting essence from three medicines by adopting a novel technology. The green medical therapy has the effects of invigorating the circulation of blood, enriching the blood, softening hard mass, clearing and regenerating, so that lens capsular injury is repaired, the permeability is restored, and lens protein denaturation, water gaps among fibers, vacuoles and cell epithelial proliferation are softened and absorbed. Therefore, a turbid crystalline lens restores to be normal, and a curative effect of improving eyesight is achieved. The medicine has an excellent effect of treating cataract and changing iris and also has a good curative effect of improving the musculus ocularis. The eye drops are easy to use and are not needed to be matched with other medicines and methods. The surgical therapy is not needed, and the traditional Chinese medicine eye drops do not have a toxic or side effect and are easy to popularize and apply.
Elucirem (Gadopiclenol) is a new macrocyclic gadolinium-based contrast agent (GBCA) with high relaxivity indicated for use in adults and children aged 2 years and older for contrast-enhanced magnetic resonance imaging. The product was approved in 2022 by FDA to be used to detect and visualize lesions with abnormal vascularity in the central nervous system (brain, spine, and associated tissues) and the body (head and neck, thorax, abdomen, pelvis, and musculoskeletal system).

Based on the investigators previous experience with 0.2 mmol/kg Dotarem, the optimal post-contrast T1 for LGE was when the remote myocardium (i.e. area without scar) had T1 of around 400ms at 12 mins post-contrast. The investigators hypothesize that with 0.05 mmol/kg Elucirem, post T1 will recover to 400 ms faster than 12 minutes after injection. It will likely be between 6 to 10 minutes post-contrast. A serial of T1 mapping will provide the information for timing. However, if myocardial T1 were not reduced short enough or recovers to 400 ms in less than 5 minutes post-contrast with 0.05 mmol/kg Elucirem, that is a sign of inadequate dose. Same evaluation will be performed for 0.075 mmol/kg Elucirem. The investigators hypothesize that if 0.05 mmol/kg falls short, 0.075 mmol/kg should be adequate. Since a single dose (0.1 mmol/kg) of Dotarem is proved to be adequate for LGE in many literatures, less Elucirem should be used to demonstrate its benefit.

Study Procedure: It is a non-randomized cohort study. Participants with precious double dose Dotarem CMR will be recruited. The study has two phases. Phase I is to evaluate the optimal dose, 0.05 mmol/kg (N=5) or 0.075 mmol/kg (N=5) by assessing a serial of the myocardial T1 mapping in normal volunteers. T1 mapping will be acquired every 2.5 minutes after injection to 25 minutes post-contrast. Based on the results of Phase I, the optimal dose will be used in the Phase II scar assessment in patients with a scar from a previous double-dose Dotarem study.
EUS-LB will be performed using a 22 g FNB needle. Specimens obtained from each pass will be placed in a separate biopsy jar. If the third pass does not result in sufficient diagnostic material, a 19 G will be used. A maximum of 3 passes will be made using the alternate needle. The total number of passes with the 22 G needle and the 19 G needle is 6. Data will be collected about the procedure and the performance of the needles for each procedure.
Following the 6-month, 16-session, DPP core program, 30-minute group telephone calls will be implemented. Structured behavioral DPP maintenance sessions with a healthy aging focus occur once-per-month from months 7 to 12, and every-two-months from months 13 to 24.
The duration of this group was 8 weeks. The program included sessions 3 times per week, with each session lasting 1 hour and 15 minutes. The volunteers performed yoga classes composed of "asana" (poses), "pranayama" (breathing exercise) and meditation.
PURPOSE: To explore the effect of acacetin on subarachnoid hemorrhage (SAH) and its possible mechanism.
METHODS: SAH model of rat was established, and intraperitoneally injected with three doses of acacetin. To verify the role of PERK pathway, we used the CCT020312 (PERK inhibitor) and Tunicamycin (activators of endoplasmic reticulum stress). The SAH score, neurological function score, brain edema content, and Evans blue (EB) exudate were evaluated. Western blot was used to determine the expression of inflammation-associated proteins and PERK pathway. The activation of microglia was also determined through Iba-1 detection. TEM and immunofluorescence staining of LC3B were performed to observe the autophagy degree of SAH rats after acacetin. Tunel/NeuN staining, HE and Nissl' staining were performed for neuronal damage.
RESULTS: Acacetin increased the neurological function score, reduce brain water content, Evans blue exudation and SAH scores. The microglia in cerebral cortex were activated after SAH, while acacetin could inhibit its activation, and decreased the expression of TNF-α and IL-6 proteins. The pathological staining showed the severe neuronal damage and increased neuronal apoptosis after SAH, while acacetin could improve these pathological changes. We also visualized the alleviated autophagy after acacetin. The expression of Beclin1 and ATF4 proteins were increased, but acacetin could inhibit them. Acacetin also inactivated PERK pathway, which could improve the neuronal injury and neuroinflammation after SAH, inhibit the microglia activation and the overactivated autophagy through PERK pathway.
CONCLUSION: Acacetin may alleviate neuroinflammation and neuronal damage through PERK pathway, thus having the protective effect on EBI after SAH.
The invention relates to a personalized treatment scheme recommendation system based on machine learning, which aims at assisting doctors in making treatment plans for individual patients by analyzing a large amount of clinical data and patient information. The system first collects and pre-processes clinical data of a patient and then extracts key features to construct feature vectors for personalized treatment regimens. These features are then trained and optimized using machine learning and artificial intelligence algorithms to form an efficient treatment plan predictive model. Finally, the system recommends personalized treatment regimens to the physician based on the model, including drug selection, dose adjustment, and possibly surgical regimens, among others. In addition, the system also comprises a result evaluation and feedback link so as to realize continuous improvement on the recommended scheme. The recommendation system can improve the medical service efficiency and ensure the individuation and scientificity of the treatment scheme, thereby improving the treatment effect of patients.
BACKGROUND: Atopic dermatitis (AD), a relapsing, inflammatory skin disease, is associated with pruritus that can negatively affect patients' quality of life. Understanding the burden of AD is critical for informing and tailoring treatment and disease management to improve patient outcomes. This study characterized global treatment patterns and the clinical, psychosocial and economic burden of moderate-to-severe AD.
METHODS: MEASURE-AD was a cross-sectional 28-country study in patients with physician-confirmed moderate-to-severe AD who were either receiving or eligible for systemic therapy for AD. Patients ≥12 years were enrolled between December 2019 and December 2020 while attending routine office or clinic visit. Primary outcomes included Worst Pruritus Numeric Rating Scale (WP-NRS; range: 0-10) and Dermatology Life Quality Index (DLQI; range: 0-30) and Children's DLQI (CDLQI; range: 0-30). Secondary outcomes included physician- and patient-reported clinical, psychosocial and economic burden.
RESULTS: Of the 1591 patients enrolled, 1558 (1434 adults and 124 adolescents) fulfilled all patient selection criteria and were included in this analysis. Almost all patients (98.4%) in the total population were using AD medications and more than half (56%) were receiving systemic medication (15% systemic monotherapy). The most used systemic therapies were dupilumab (56.3%), systemic glucocorticoids (18.1%) and methotrexate (16.2%). Mean WP-NRS was 5.3 in the total population, and most patients (≥55%) reported moderate-to-severe pruritus (WP-NRS ≥4). Mean DLQI was 10.8 and mean CDLQI was 9.6. Secondary endpoints demonstrated substantial clinical, psychosocial, and economic burden of disease. Subgroup analysis demonstrated that patients receiving systemic therapy had lower disease burden than those not taking systemic medications.
CONCLUSIONS: While systemic therapy lowers overall disease burden, patients with moderate-to-severe AD continue to have substantial multidimensional disease burden and uncontrolled disease. Overall, there is a need for effective disease management, including effective treatments that improve patients' psychosocial outcomes and reduce the economic burden of AD.
The tauopathies encompass over 20 adult neurodegenerative diseases and are characterized by the dysfunction and accumulation of insoluble tau protein. Among them, Alzheimer's disease, frontotemporal dementia, and progressive supranuclear palsy collectively impact millions of patients and their families worldwide. Despite years of drug development using a variety of mechanisms of action, no therapeutic directed against tau has been approved for clinical use. This raises important questions about our current model of tau pathology and invites thoughtful consideration of our approach to nonclinical models and clinical trial design. In this article, we review what is known about the biology and genetics of tau, placing it in the context of current and failed clinical trials. We highlight potential reasons for the lack of success to date and offer suggestions for new pathways in therapeutic development. Overall, our viewpoint to the future is optimistic for this important group of neurodegenerative diseases.
Patients undergo 1, 5, or 10 fraction of SRS/SRT radiation. Surgery is performed within 72 hours of radiation therapy.
Patients will work with a Community Health Worker (CHW) to complete a prioritization tool and meet as needed over the course of the next 6 months to navigate services and overcome barriers. In addition, patients will receive referrals to other professionals based on their prioritization and meet with the CHW at the time and place of their choice.
The invention relates to a preparation method of an all-natural skin-fragrant cleansing deodorant. This product is developed with respect to current human body stinking smell due to perspiration. Human secretory sweat glands generally include eccrine sweat glands and apocrine sweat glands. The eccrine sweat glands are distributed in the whole body, while the apocrine sweat glands are distributed in armpits, mammary areolas, private parts and the like. Sweat itself is odorless, but stinks after being mixed with germs on the surface of skin. The invention aims to develop an all-natural skin-fragrant cleansing (disinfecting) deodorant, comprises main materials: edible seawater salt, alum, edible magnesium oxide, amino acid iodine, rosemary and the like and is finely made using modern scientific methods. This deodorant is a skin-care cleansing (disinfecting) deodorant. Researches prove that human body sweat is odorless. This deodorant of the invention is effective in eliminating (by deactivating) interference of germs upon human sweat glands, giving fragrant and healthy skin to everyone throughout the world.
The intervention includes Facebook-delivered weight loss counseling and the use of Slip Buddy, an app created by the investigative team that only requires users to record instances of overeating by hitting a single button and then indicate the overeating trigger and stress and hunger levels. The intervention will last for 12 weeks. In addition to the weight loss counseling, participants will be asked to use the Slip Buddy app during the intervention period (12 weeks). Participants will receive a Fitbit scale to take their weight weekly and at assessments.
Patients would receive Tivozanib 1.0 mg/day orally, 3 weeks on, one week off, for one cycle starting day 1. If no adverse event is encountered, patients will continue subsequent cycles of Tivozanib 1.5 mg/day orally; 3 weeks on/1 week off, dosing schedule. Patients will continue on treatment until disease progression, unacceptable toxicity, or patient withdrawal from the study.